ArticleOphthalmology science
Impact of the Coronavirus Disease 2019 Pandemic on Initiation Therapy for Noninfectious Uveitis.
Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Initial studies during the coronavirus disease 2019 (COVID-19) pandemic demonstrated a possible increased risk of COVID-19 infection and severe outcomes with prior or concurrent immunomodulatory therapy (IMT). The purpose of this study was to determine the impact of the COVID-19 pandemic on treatment patterns for noninfectious uveitis (NIU). Design: Retrospective interrupted time series (ITS) analysis using Optum Labs Data Warehouse, a national deidentified health care database in the United States with administrative claims and electronic health record data. Participants: Individuals with a new diagnosis of NIU from December 1, 2017, to December 31, 2020, with continuous enrollment ≥1 year before this diagnosis. Methods: This study was divided into 3 time periods: prepandemic (December 1, 2017-November 30, 2019), early pandemic (March 1, 2020-December 31, 2020), and postvaccine period (January 1, 2021-September 30, 2021) corresponding to time before the pandemic, during the pandemic when no COVID-19 vaccine was available, and after widespread utilization of the vaccine began. Normalized prescription rates of uveitis therapies were modeled as an ITS. In the time-to-treatment analysis, Cox proportional hazard models were used to determine differences in likelihood of different modalities between time periods. Main Outcome Measures: Temporal trends in the initial therapeutic choice for NIU. Results: This study included 22 444 patients with a new NIU diagnosis. The average age was 61.9 (standard deviation 17.5) years, and 59.3% were female. There were no significant temporal breaks in prescribing trends for topical, local, and systemic corticosteroids or immunosuppressive therapy (disease-modifying antirheumatic drugs and biologics) between pandemic periods (all Conclusions: No significant differences in prescribing patterns for NIU were observed between pandemic periods. However, utilization of topical and local steroids for NIU was, overall, increased in the early compared with the prepandemic period. Financial Disclosures: The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.